Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma

Cancer Science

Volumn 99, Issue 2, 2008, Pages 368-375

  Tsukahara, Tomohide ^a   Kawaguchi, Satoshi ^a   Torigoe, Toshihiko ^a   Kimura, Shigeharu ^a   Murase, Masaki ^a   Ichimiya, Shingo ^a   Wada, Takuro ^a   Kaya, Mitsunori ^a   Nagoya, Satoshi ^a   Ishii, Takeshi ^b   Tatezaki, Shin Ichiro ^b   Yamashita, Toshihiko ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A24 ANTIGEN; HLA B ANTIGEN; PAPILLOMAVIRUS BINDING FACTOR; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASSAY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL KILLING; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; FEMALE; FREQUENCY ANALYSIS; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIXED LYMPHOCYTE CULTURE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; T LYMPHOCYTE; TUMOR BIOPSY;

ADOLESCENT; ADULT; ALLELES; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CHILD; DNA-BINDING PROTEINS; FEMALE; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; OSTEOSARCOMA; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS;

EID: 38949215429     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00695.x     Document Type: Article

References (40)

1. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-52.
2. Lewis VO. What's new in musculoskeletal oncology. J Bone Joint Surg Am 2007; 89: 1399-407.
3. Campbell CJ, Cohen J, Enneking WF. Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg Am 1975; 57: 143-4.
4. Kawaguchi S, Wada T, Tsukahara T et al. A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med 2005; 3: 31.
5. Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004-11.
6. Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363-8.
7. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D, Part I. Vaccines for solid tumours. Lancet Oncol 2004; 5: 681-9.
8. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 35: 9008-21.
9. Thurner B, Haendle I, Roder C et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
10. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
11. Nabeta Y, Kawaguchi S, Sahara H et al. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 2003; 8: 554-9.
12. Tsukahara T, Nabeta Y, Kawaguchi S et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004; 64: 5442-8.
13. Boeckle S, Pfister H, Steger G. A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology 2002; 293: 103-17.
14. Sichtig N, Silling S, Steger G. Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14-3-3 beta. Arch Biochem Biophys 2007; 464: 90-9.
15. Tsukahara T, Kawaguchi S, Ida K et al. HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res 2006; 24: 94-101.
16. Al-Batran SE, Rafiyan MR, Atmaca A et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65: 3937-41.
17. Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 1374-80.
18. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; 204: 9-24.
19. Rosen G, Nirenberg A. Neoadjuvant chemotherapy for osteogenic sarcoma: A five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res 1985; 201: 39-51.
20. Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 1996; 53: 221-7.
21. Yonemoto T, Tatezaki S, Ishii T, Satoh T, Kimura H, Iwai N. Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 1998; 349: 194-9.
22. Ishii T, Tatezaki S. The results of a cooperative study of chemotherapy for osteosarcoma (NECO 93J). J Jpn Orthop Assoc 1999; 73: S1129.
23. Isu K, Yamawaki S, Beppu Y et al. Prognostic results from multi-institute study of adjuvant chemotherapy for osteogenic sarcoma. J Jpn Orthop Assoc 1999; 73: S1135.
24. Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J Bone Joint Surg Br 2004; 86: 143-7.
25. The JOA Musculo-Skeletal Tumor Comittee. General Rules for Clinical and Pathological Studies on Malignant Bone Tumors, 2nd edn. Tokyo: Kanabara, 2000.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-75.
27. +) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-81.
28. Ida K, Kawaguchi S, Sato Y et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004; 173: 1436-43.
29. Karanikas V, Lurquin C, Colau D et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171: 4898-904.
30. +) patients with synovial sarcoma. J Immunol 2002; 169: 1611-8.
31. Dagher R, Long LM, Read EJ et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Med Pediatr Oncol 2002; 38: 158-64.
32. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
33. Yabe H, Tsukahara T, Kawaguchi S et al. Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors coferring poor prognosis. Oncol Rep 2007; 19: 129-34.
34. Lurquin C, Lethe B, De Plaen E et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201: 249-57.
35. Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290-5.
36. So T, Hanagiri T, Chapiro J et al. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 2007; 56: 259-69.
37. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: Does function matter more than number? Curr Opin Immunol 2005; 17: 320-5.
38. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
39. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.
40. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006; 92: 187-224.